A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

NCT06109311 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effectiveness of the medication Orforglipron in adults with type 2 diabetes whose blood sugar is not well controlled with insulin glargine, with or without metformin and/or SGLT-2 inhibitors.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 546 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-11 · est. completion 2025-09

Where 70 sites · Brazil, China, Japan, Puerto Rico, Romania, United States

What this study is testing ClinicalTrials.gov NCT06109311 ↗

Description as written by the study sponsor.

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally.
Placebo Drug

Administered orally.

Main thing measured	Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06109311 ↗